Enterprise Value
1.774B
Cash
410.7M
Avg Qtr Burn
-30.65M
Short % of Float
26.02%
Insider Ownership
1.24%
Institutional Own.
93.70%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Rapivab (peramivir) Details Influenza | Approved Quarterly sales | |
Orladeyo (Berotralstat) Details Rare diseases, Rare genetic disease, Hereditary angioedema | Approved Quarterly sales | |
BCX10013 (Oral Factor D inhibitor) Details Complement mediated diseases, Paroxysmal nocturnal hemoglobinuria | Phase 1 Initiation | |
BCX9250 (ALK2 inhibitor) Details Fibrodysplasia ossificans progressiva | Failed Discontinued | |
Galidesivir (BCX4430) Details COVID-19 | Failed Discontinued | |
BCX9930 (Oral Factor D inhibitor) Details Paroxysmal nocturnal hemoglobinuria | Failed Discontinued |